| Line Item | 2026-03-31 | Q/Q | Y/Y |
|---|---|---|---|
| R&D Expense | $14.1M | — | +5.1% |
| SG&A Expense | $8.1M | — | +15.8% |
| Operating Income | -$22.2M | — | -8.7% |
| Net Income | -$18.9M | — | -7.0% |
| EPS (Basic) | -$0.25 | — | +10.7% |
| EPS (Diluted) | -$0.25 | — | +10.7% |
| Line Item | 2026-03-31 | Q/Q | Y/Y |
|---|---|---|---|
| Cash & Equivalents | $50.3M | -74.6% | +19.2% |
| Current Assets | $338.7M | -5.3% | +45.6% |
| Total Assets | $346.8M | -5.3% | +42.9% |
| Current Liabilities | $9.9M | -24.4% | +21.8% |
| Total Liabilities | $13.5M | -22.1% | -4.9% |
| Stockholders' Equity | $333.3M |
| Line Item | 2026-03-31 | Q/Q | Y/Y |
|---|---|---|---|
| Operating Cash Flow | -$18.8M | — | -22.9% |
| Capital Expenditures | $8K | — | — |
| Investing Cash Flow | -$128.2M | — | — |
| Financing Cash Flow | -$312K | — | — |
| Free Cash Flow | -$18.8M | — | -22.9% |
| +45.9% |